Bevacizumab is a vascular endothelial growth factor (VEGF) inhibitor approved by the FDA for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, cervical cancer and metastatic renal cell carcinoma [210]. This evidence concerns the gene VEGFA and metastatic colorectal cancer.